Find a Study

STUDY SEARCH RESULTS

Notify Me When Search is Updated

16 studies found for your search request: Mk2870

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients with Bladder Cancer (MK-2870-027)
Condition: Non-Muscle Invasive Bladder Cancer
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT06637423
Status: Recruiting
Has Enrolling Locations in US or Canada

A clinical study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) in people with breast cancer (MK-2870...
Condition: Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT06966700
Status: Recruiting
Has Enrolling Locations in US or Canada

A Study of Sacituzumab tirumotecan (MK-2870) as a Single Agent and in Combination with Pembrolizumab...
Condition: Breast Neoplasms
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT06312176
Status: Recruiting
Has Enrolling Locations in US or Canada

A Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) as Monotherapy and in Combination with Pembrol...
Condition: Triple Negative Breast Neoplasms
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT06841354
Status: Recruiting
Has Enrolling Locations in US or Canada

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab tirumotecan (MK- ...
Condition: Non small cell lung cancer
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT06312137
Status: Recruiting
Has Enrolling Locations in US or Canada

Copyright © 2025 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences Privacy Terms of Use Consumer Health Data Privacy Policy Your Privacy Choices Accessibility U.S. Corporate Site